Ophthalmologica
Original Paper · Travail original · Originalarbeit
The Short-Term Effect of Adding Brimonidine 0.2% to Timolol Treatment in Patients with Open-Angle GlaucomaYüksel N. · Altıntaş Ö. · Karabaş L. · Alp B. · Çağlar Y.Department of Ophthalmology, School of Medicine, Kocaeli University, Kocaeli, Turkey
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: July 09, 1999
Issue release date: July – August
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 4
ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)
For additional information: https://www.karger.com/OPH
Abstract
Brimonidine, a highly selective α2-adrenoceptor agonist, was studied to determine its ocular hypotensive effect and side effects in patients with elevated intraocular pressure (IOP) while on continuing therapy with timolol. This was a prospective, randomized, placebo-controlled study in 15 patients with primary open-angle or pseudoexfoliation glaucoma on therapy receiving timolol 0.5% twice daily, with IOP greater than or equal to 22 mm Hg in one eye. IOP measurements, blood pressure and pulse rate were assessed on 2 days at a baseline and 1, 2, 4, 6 and 8 h later. A single drop of brimonidine 0.2% or placebo was added to treatment with timolol. The reductions in IOP at all time intervals observed with brimonidine + timolol were significantly greater than those with timolol + placebo. The maximum mean net decrease in IOP was 19.23 ± 10.60% at 4 h. Statistically significant decreases in systemic blood pressure and pulse rate without clinical symptoms were observed in the group receiving brimonidine + timolol. This study suggests that a combination of brimonidine and timolol may have potential in the treatment of glaucoma. Further clinical trials with brimonidine are indicated to assess its further role as adjunctive agent.
Related Articles:
References
-
Camras CB: Clinical applications of α2-adrenergic agonists in ophthalmology. J Glaucoma 1995;4(suppl 1):30–35.
-
Robin AL: Apraclonidine hydrochloride: Its past, present, and future in the therapy of chronic glaucoma. J Glaucoma 1995;4(suppl 1):24–29.
- Stewart WC, Laibovitz R, Horwitz B, Stewart RH, Ritch R, Kottler M: Apraclonidine primary therapy study group: A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Arch Ophthalmol 1996;114:938–942.
- Morrison JC, Robin AL: Adjunctive glaucoma therapy: A comparison of apraclonidine to dipivefrin when added to timolol maleate. Ophthalmology 1989;96:3–7.
- Yaldo MK, Shin DH, Parrow KA, Lee SH, Lee YL: Additive effect of 5% apraclonidine hydrochloride to nonselective beta-blockers. Ophthalmology 1991;98:1075–1078.
- Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE, van Buskirk EM: Apraclonidine adjunctive therapy study group: The efficacy of apraclonidine as an adjunct to timolol therapy. Arch Ophthalmol 1995;113:287–292.
-
Derick RJ: Adrenergic agonist medications: Basic mechanisms. J Glaucoma 1995;4(suppl):1–7.
- Toris CB, Gleason ML, Camras CB, Yablonski ME: Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514–1517.
- David R, Spaeth GL, Clevenger CE, Perell H, Siegel LI, Henry JC, Stiles MC, Passo MS, Stamper RL, Walt JG, Kelley EP, Chen KS: Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch Ophthalmol 1993;111:1387–1390.
- Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J: The cardiovascular, pulmonary and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995;113:77–83.
- Derick RJ, Robin AL, Walters TR, Barnebey HS, Choplin N, Schuman J, Kelley EP, Chen K, Stoecker JF: Brimonidine tartrate: A one-month dose response study. Ophthalmology 1997;104:131–136.
-
Serle JB, The brimonidine study group III: A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol 1996;41(suppl 1):39–47.
- Gunning F, Bechetoille A, Lippa EA, Pfeiffer N, Gerling J, Holder D, Clineschmidt C, Buntinx A, Brunner-Ferber FL, Grehn F, Greve E: Sezolamide: Additivity to timolol twice daily. Eye 1992;6:525–529.
- Strahlman ER, Vogel R, Tipping R, Clineschmidt CM: The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996;103:283–292.
-
Laibovitz R, Strahlman ER, Barber BL, Strohmaier KM: Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J Glaucoma 1995;4:306–313.
- Gharagozloo NZ, Refl SJ, Brubaker RF: Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology 1988;95:1217–1220.
-
Kaufman PL, Gabelt B: α2-Adrenergic agonist effects on aqueous humor dynamics. J Glaucoma 1995;4(suppl 1):8–14.
- Coates RL, Brubaker RF: The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol 1978;96:2045–2048.
- Gharagozloo NZ, Brubaker RF: Effect of apraclonidine in long-term timolol users. Ophthalmology 1991;98:1543–1546.
- Barnebey HS, Robin AL, Zimmermen TJ, Morrison JC, Hersh SB, Lewis RA, Coleman AL, Cinotti DJ, Walt J, Chen KS, Kelley EP: The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology 1993;100:1083–1088.
-
Schuman JS: Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41(suppl 1):27–37.
- Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen KK, the chronic brimonidine study group: A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: A controlled, randomised, multicenter clinical trial. Arch Ophthalmol 1997;115:847–852.
- Butler P, Mannschreck M, Lin S, Hwang I, Alvarado J: Clinical experience with the long-term use of 1% apraclonidine. Arch Ophthalmol 1995;113:293–296.
- Araujo SV, Bond JB, Wilson RP, Moster MR, Schmidt CM, Spaeth GL: Long-term effect of apraclonidine. Br J Ophthalmol 1995;79:1098–1101.
-
Morrison JC: Side effects of α-adrenergic agonists. J Glaucoma 1995;4(suppl 1):36–38.
Article / Publication Details
Published online: July 09, 1999
Issue release date: July – August
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 4
ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)
For additional information: https://www.karger.com/OPH
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
